Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $11.91

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $11.91.

Several equities research analysts have commented on the stock. Evercore ISI upped their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Stephens dropped their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. upped their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Wednesday, September 4th. Finally, Piper Sandler dropped their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an "overweight" rating on the stock in a report on Monday, August 26th.

Health Catalyst Trading Down 3.4 %

Shares of NASDAQ:HCAT traded down $0.27 during midday trading on Thursday, reaching $7.77. The company had a trading volume of 720,284 shares, compared to its average volume of 563,133. The company's 50 day moving average price is $7.93 and its 200 day moving average price is $7.03. The stock has a market cap of $469.85 million, a P/E ratio of -4.35 and a beta of 1.32. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.04. The company had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm's quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) EPS. Research analysts forecast that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $6.19, for a total transaction of $32,243.71. Following the transaction, the chief operating officer now owns 150,006 shares in the company, valued at $928,537.14. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,396 shares of company stock worth $258,415. Insiders own 2.70% of the company's stock.

Institutional Trading of Health Catalyst

A number of institutional investors have recently made changes to their positions in the stock. Impax Asset Management Group plc boosted its stake in shares of Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company's stock valued at $20,793,000 after purchasing an additional 360,201 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock valued at $96,000 after purchasing an additional 2,064 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $897,000. Nepsis Inc. boosted its stake in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company's stock valued at $17,131,000 after purchasing an additional 851,448 shares during the period. Finally, nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $59,000. Hedge funds and other institutional investors own 85.00% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.